A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Condition: Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease Intervention: Drug: macitentan 10 mg Sponsors: Actelion; Almac Clinical Technologies, LLC; Frontier Science& Technology Research Foundation, Inc.; Covance Central Laboratory Services, LP; Chiltern International Ltd.; WorldCare Clinical, LLC; AcitGraph Corp.; Medidata Solutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials